Latest Dorsavi (ASX:DVL) News

dorsaVi has inked a five-year sales agreement with Select Medical, opening access to over 1,900 US outpatient physical therapy centers for its FDA-approved motion analysis products. This follows a successful 18-month pilot validating clinical benefits in athlete rehabilitation.

DorsaVi Limited reported a 13.9% revenue decline and a 21.7% rise in net loss for FY25, while securing over $3 million in capital to fuel new technology ventures.

dorsaVi appoints Mathew Regan as Group CEO to spearhead commercialisation of next-gen RRAM-enabled AI and robotics technologies, aiming for global expansion.

dorsaVi Ltd has unveiled Artemis Labs, a new subsidiary focused on developing advanced AI, sensor, and robotics technologies powered by cutting-edge RRAM. This initiative aims to transform human movement data into intelligent robotic and healthcare applications.

dorsaVi Ltd has raised A$5 million through a strategic placement to accelerate development of its next-generation RRAM-enabled sensors and robotics platforms, signaling a bold expansion into edge AI and neuromorphic computing.

dorsaVi Ltd is expanding its RRAM technology evaluation to next-generation robotics, aiming to deliver sub-millisecond reflexes that could revolutionize safety and dexterity in collaborative robots and wearables.

dorsaVi has acquired exclusive global rights to advanced RRAM technology, promising major performance gains in its biomedical sensors, while securing key contracts and raising $2.44 million to fuel US market growth.

dorsaVi reports transformative performance improvements from integrating RRAM technology into its biomedical sensor platforms, promising faster, more durable, and energy-efficient wearable devices.

dorsaVi confirms its licensed 40nm Resistive RAM technology delivers high-speed, low-power performance ideal for next-generation embedded and edge AI platforms. This breakthrough supports advanced wearable sensors and neuromorphic computing applications.

dorsaVi has begun critical testing of its innovative RRAM-powered sensor systems in Singapore, targeting biomedical applications like EMG and ECG to enhance wearable device performance and energy efficiency.

dorsaVi has secured exclusive worldwide rights to cutting-edge RRAM technology from NTU Singapore, promising to revolutionize its wearable sensor products with enhanced performance and energy efficiency. This strategic move positions the company for expansion into healthcare, elite sports, and industrial IoT markets.

dorsaVi has secured a three-year agreement with SANO Health to deploy its ViSafe+ wearable sensor technology across remote mining sites, reinforcing its foothold in high-risk occupational health sectors.